Topics

FDA expands indication for Regeneron, Sanofi's Praluent

06:21 EDT 29 Apr 2019 | SmartBrief

Regeneron Pharmaceuticals and Sanofi's Praluent has been approved by the FDA for use to reduce the overall risk of major adve -More

Original Article: FDA expands indication for Regeneron, Sanofi's Praluent

NEXT ARTICLE

More From BioPortfolio on "FDA expands indication for Regeneron, Sanofi's Praluent"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...